Chart of the Day: Immunovant (IMVT)
Keep an eye on Immunovant (IMVT). While the stock exploded about $20 higher, analysts believe it could push even higher. All after the company's early-stage data from its experimental antibody treatment – IMVT-402 -- exceeded analysts' expectations. If successful,...










